OXFORD BIODYNAMICS LS-01
Research OXFORD BIODYNAMICS LS-01 (LMQ) on Bullrun: market cap EUR 2.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLMQ
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 2.15M
- Financial periodFY2025
- RevenueGBP 1.10M
- Revenue growth72.2%
- Net income-GBP 11.15M
- Free cash flow-GBP 7.82M
- Gross margin47.7%
Valuation Snapshot
latest market cap is EUR 2.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 1.10M | -GBP 11.15M | -GBP 7.82M | 47.7% | -0.01 | GBP 1.39M | GBP 5.11M | GBP 1.12M |
| FY2024 | GBP 636.00K | -GBP 11.57M | -GBP 10.77M | 45.4% | -0.05 | GBP 1.83M | GBP 5.74M | GBP 4.36M |
| FY2023 | GBP 510.00K | -GBP 10.83M | -GBP 9.01M | 52.2% | -0.07 | GBP 5.25M | GBP 6.44M | GBP 6.06M |
| FY2022 | GBP 154.00K | -GBP 6.71M | -GBP 6.08M | 75.3% | -0.07 | GBP 974.00K | GBP 6.14M | GBP 2.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | EUR 2.15M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About OXFORD BIODYNAMICS LS-01
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OXFORD BIODYNAMICS LS-01's market cap?
OXFORD BIODYNAMICS LS-01's market capitalization is EUR 2.15M.
What does OXFORD BIODYNAMICS LS-01 do?
Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker.